
Horizon Discovery licenses platform to TrueBinding for biotherapeutics development
TrueBinding, a biopharmaceutical company, has signed a set of commercial licenses for Horizon Discovery’s CHOSOURCE platform. TrueBinding will use the cGMP-compliant platform for the development and commercialisation of multiple biotherapeutic products for applications in immuno-oncology and other disease areas with great unmet medical need. Horizon’s CHOSOURCE platform includes a gene-edited… Read More















